[HTML][HTML] AKT-AMPKα-mTOR-dependent HIF-1α activation is a new therapeutic target for cancer treatment: a novel approach to repositioning the antidiabetic drug …
HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug …
EE Abd El-Fattah, S Saber… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug …
AEF EE, S Saber, ME Youssef, H Eissa… - Frontiers in …, 2022 - europepmc.org
HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
[HTML][HTML] AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug …
EE Abd El-Fattah, S Saber, ME Youssef… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
[PDF][PDF] AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug …
EE Abd El-Fattah, S Saber, ME Youssef… - Front. Pharmacol. 12 …, 2022 - researchgate.net
ORIGINAL RESEARCH published: 12 January 2022 doi: 10.3389/fphar. 2021.720173
prolonged the survival, restored the histological features and improved liver function …
prolonged the survival, restored the histological features and improved liver function …
[PDF][PDF] AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug …
EE Abd El-Fattah, S Saber, ME Youssef… - Front. Pharmacol. 12 …, 2022 - academia.edu
ORIGINAL RESEARCH published: 12 January 2022 doi: 10.3389/fphar. 2021.720173
prolonged the survival, restored the histological features and improved liver function …
prolonged the survival, restored the histological features and improved liver function …
[PDF][PDF] AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug …
EE Abd El-Fattah, S Saber, ME Youssef… - Front. Pharmacol. 12 …, 2022 - academia.edu
ORIGINAL RESEARCH published: 12 January 2022 doi: 10.3389/fphar. 2021.720173
prolonged the survival, restored the histological features and improved liver function …
prolonged the survival, restored the histological features and improved liver function …
AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug …
AEF EE, S Saber, ME Youssef, H Eissa… - Frontiers in …, 2022 - europepmc.org
HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …
well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT …